VICL (Vical Labs) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: foundation who wrote (271)	6/11/1997 2:10:00 PM
From: tonyt	of 1972

GeneMedicine, Vical Get Lehman Initial Ratings Coverage ============================================================= NEW YORK -(Dow Jones)- Lehman Brothers Inc. analyst Matthew Murray said he initiated coverage of GeneMedicine Inc. (GMED) at "venture outperform" and Vical Inc. (VICL) at "outperform." Murray has 12-month share-price targets of $14 for GeneMedicine and 20 for Vical. GeneMedicine shares recently were up $0.25 at $8.50, and Vical shares were up $0.375 at $13.25. Copyright (c) 1997 Dow Jones & Company, Inc. All Rights Reserved.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next